Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) Sees Large Inflow of Net Money Flow

Teva Pharmaceutical Industries Limited (NYSE:TEVA) dropped by -0.02 or -0.01 points during the last session to $53 per share. One of the highlights of the day was the net money flow figure, which stood at $2.71 million even as the stock accepted $23.3 million in upticks but rejected $20.59 million in downticks. The up/down ratio for the last observation was a 1.13. The 1-week percentage change for the stock price is registered at -1.47%.A block transaction occurred with $9.06 million in upticks and $5.5 million in downticks while the up/down ratio was calculated to be 1.65. The stock witnessed a net inflow of $3.56 million at the end of the block trade.


Currently the company Insiders own 7.1% of Teva Pharmaceutical Industries Limited shares according to the proxy statements. Institutional Investors own 64.03% of Teva Pharmaceutical Industries Limited shares.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) : On Monday heightened volatility was witnessed in Teva Pharmaceutical Industries Limited (NYSE:TEVA) which led to swings in the share price. The stock opened for trading at $52.96 and hit $53.91 on the upside , eventually ending the session at $53.22, with a gain of 0.4% or 0.21 points. The heightened volatility saw the trading volume jump to 3,977,131 shares. The 52-week high of the share price is $72.31 and the company has a market cap of $48,643 million. The 52-week low of the share price is at $49.51 .

Many analysts have stated their opinion on the company shares. Credit Suisse initiates coverage on Teva Pharmaceutical Industries Limited (NYSE:TEVA). In the latest research report, Credit Suisse announces the target price to $60 per share. According to the latest information available, the shares are now rated Neutral by the analysts at the agency. The rating by the firm was issued on May 4, 2016.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.